1 What was known before:

 $\mathbf{2}$

3	Intravitreal bevacizumab (IVB) has been widely used to treat myopic choroidal
4	neovascularization (mCNV). Earlier studies reported good visual outcomes
5	after one to two year follow-ups, however there is still not enough information
6	available that helps us to predict visual outcome for each patient.
7	
8	What this study adds:
9	
10	The results of our study showed that the CNV lesion size was a prognostic
11	factor after IVB for mCNV; patients with smaller mCNVs had better visual
12	recovery and better best-corrected visual acuity (BCVA) at 24 months after
13	initial IVB than those with larger mCNV. The results of our study also showed
14	that patients with more impaired visual acuity before treatment got higher
15	visual recovery, however, this might be due to ceiling/floor effect.

Prognostic Factors in IVB for myopic CNV. Nakanishi H, et al. Page 2

1	Prognostic Factors for Visual Outcomes Two-Years after
2	Intravitreal Bevacizumab for Myopic Choroidal Neovascularization
3	
4	Hideo NAKANISHI ¹ , Akitaka TSUJIKAWA ¹ , Yuko YODOI ^{1,2} , Yumiko OJIMA ¹ , Atsushi
5	OTANI ¹ , Hiroshi TAMURA ¹ , Kenji YAMASHIRO ¹ , Sotaro OOTO ¹ , and Nagahisa
6	YOSHIMURA ¹
7	¹ Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of
8	Medicine, Kyoto, Japan
9	² Department of Ophthalmology, Kyoto-Katsura Hospital, Kyoto, Japan
10	
11	Correspondence to: Akitaka Tsujikawa, MD, Department of Ophthalmology and Visual Sciences,
12	Kyoto University Graduate School of Medicine, Kyoto, Japan
13	E-mail: <u>tujikawa@kuhp.kyoto-u.ac.jp</u>
14	
15	Short running title: Prognostic Factors in IVB for myopic CNV.
16	Key words: myopic choroidal neovasculariation, bevacizumab, prognostic factor, intravitreal
17	injection
18	The text in this article includes 2,888 words (excluding abstract, references, figures and tables).

The study was supported in part by grants-in-aid for scientific research (No. 21249084) from the Japan Society for the Promotion of Science, Tokyo, Japan, and by the Japanese National Society for the Prevention of Blindness. The authors indicate no financial conflict of interest.

4

1 Abstract (247/250 words)

 $\mathbf{2}$

3	Purpose: To determine the pre-treatment ocular factors significantly associated with the visual
4	outcome 24 months after intravitreal bevacizumab (IVB) for myopic choroidal
5	neovascularization (mCNV).
6	Methods: Twenty-three eyes of 23 patients with mCNV were treated with IVB followed by as
7	needed therapy. The efficacy of IVB was evaluated by the best-corrected visual acuity (BCVA)
8	at 24 months after the initial treatment. Forward stepwise multiple linear regression analyses
9	were performed to evaluate the influence of pre-treatment factors on the BCVA and the
10	improvement of the BCVA at 24 months.
11	Results: The mean pre-IVB BCVA was 0.74 ± 0.30 logarithm of the minimum angle of
12	resolution (logMAR) units, and it improved to 0.43 ± 0.31 logMAR units after one month
13	($P < 0.001$, paired t test). The improvement was maintained at 24 months (0.46 ± 0.40 , $P < 0.005$).
14	The mean number of IVB performed during the 24 months was 1.35 ± 0.71 . Forward stepwise
15	regression analysis showed that the pre-IVB CNV size (standardized β =0.52, P<0.01) and
16	BCVA (standardized β =0.44, <i>P</i> <0.05) significantly affected the visual acuity change after 24
17	months. The CNV size was the only factor that significantly affected the BCVA after 24
18	months (standardized $\beta = 0.56$, $P < 0.01$).

1	Conclusions:	IVB with as needed therapy for mCNV led to a rapid and sustained visual
2	improvement.	Smaller CNV size was a significant prognostic factor that predicts better visual
3	acuity. Patien	ts with lower pre-treatment BCVA had better visual recovery than those with
4	better pre-treat	ment BCVA, however this may be due to a ceiling/floor effect.
5		

1 Introduction

 $\mathbf{2}$

3	Choroidal neovascularization (CNV) is a vision-threatening complication in eyes with
4	pathological myopia. Myopic choroidal neovascularizations (mCNVs) have been shown to
5	develop in 5% to 10% of the eyes with pathological myopia, ¹⁻³ and several studies have shown
6	that mCNVs have a poor natural history. ⁴⁻⁶ For example, the visual acuity at five years after the
7	onset of CNV decreased to $\leq 20/200$ in 89% of the eyes and in 96% of the eyes after 10 years. ⁶
8	Because of the poor natural history of mCNVs, several procedures have been tried to treat
9	mCNVs, e.g., thermal laser photocoagulation, ⁷ photodynamic therapy (PDT) with verteporfin
10	(Visudyne, Novartis Pharma AG, Basel, Switzerland), ⁸ and intravitreal bevacizumab (Avastin;
11	Genentech, South San Francisco, California), a recombinant humanized monoclonal anti-VEGF
12	antibody. Earlier case series have reported good visual outcomes one to two years after
13	intravitreal bevacizumab (IVB),9-21 and at present IVB would be the first-line therapy for sub-
14	and juxtafoveal mCNVs. ²² However, there is still not enough information to predict the visual
15	outcome of each patient with mCNV treated with IVB.
16	Thus, the purpose of this study was to determine the long-term visual outcome of IVB in
17	eyes with mCNVs. We also determined which pre-IVB factors were significantly associated
18	with the visual outcome two-years after the IVB therapy.

1

2 Patients and Methods

3

4	All of the procedures used in this study were approved by the Institutional Review Board at
5	Kyoto University Graduate School of Medicine, and they conformed to the tenets of the
6	Declaration of Helsinki. A written informed consent was obtained from each patient.
7	In this nonrandomized, noncomparative case series, we reviewed the medical records of
8	patients with myopic CNV who were treated with IVB at the Kyoto University Hospital between
9	December 1st 2006 and December 31th 2007. Before the IVB, all of the patients received a
10	comprehensive ophthalmologic examination, including best-corrected visual acuity (BCVA),
11	intraocular pressure measurements, indirect ophthalmoscopy, slit-lamp biomicroscopy with a
12	contact lens, fundus photography, optical coherence tomography (OCT), and
13	fluorescein/indocyanine green angiography (FA/IA) using a confocal laser scanning system
14	(HRA-2; Heidelberg Engineering, Heidelberg, Germany). The Stratus OCT3000 (Carl Zeiss,
15	Dublin, California) or the OCT ophthalmoscope C7 (Nidek, Gamagori, Japan) examination of
16	cross-sections (5-6 mm in length) centered on the fovea and on the mCNV were performed at the
17	baseline examination. The size of the mCNV before treatment was measured on the FA/IA
18	images using the embedded software programs in the HRA-2. The BCVA was measured with a

1	Landolt chart, and the decimal values were converted to the logarithm of the minimal angle of
2	resolution (logMAR) units.

3	The inclusion criteria were: (1) an axial length of \geq 26.50 mm or spherical equivalent
4	refractive error of \geq -6.0 diopters (D) in phakic eyes; (2) fundus changes typical of pathologic
5	myopia, such as chorioretinal atrophy, lacquer cracks, or atrophic patches; (3) FA documentation
6	of subfoveal or juxtafoveal CNV that showed active leakage; and (4) BCVA of \geq 1.3 logMAR
7	units (0.05 decimal units, 10/200 in Snellen acuity). The exclusion criteria were: (1) history of
8	intraocular surgery except for cataract surgery; (2) prior treatment for the mCNV; and (3) other
9	ocular disease that can influence the BCVA, such as corneal opacity or myopic foveoschisis. In
10	patients who had undergone IVB in both eyes, the data from the right eye was used for the
11	statistical analyses.
11 12	statistical analyses. All patients who had a recent visual disturbance due to active subfoveal or juxtafoveal
12	All patients who had a recent visual disturbance due to active subfoveal or juxtafoveal
12 13	All patients who had a recent visual disturbance due to active subfoveal or juxtafoveal mCNV were offered the IVB treatment with an explanation of possible complications. The
12 13 14	All patients who had a recent visual disturbance due to active subfoveal or juxtafoveal mCNV were offered the IVB treatment with an explanation of possible complications. The intravitreal dose of bevacizumab was 1.25 mg/0.05 ml. All injections were performed in a
12 13 14 15	All patients who had a recent visual disturbance due to active subfoveal or juxtafoveal mCNV were offered the IVB treatment with an explanation of possible complications. The intravitreal dose of bevacizumab was 1.25 mg/0.05 ml. All injections were performed in a sterile manner, and prophylactic topical antibiotics were applied from a few days before to 1

1	examinations such as angiography were performed as needed. Retreatment with IVB was
2	performed if the evaluating clinician judged a re-injection was needed. The re-injection criteria
3	were any of following finding with visual loss at least one month after the previous IVB: (1)
4	persistence or recurrence of macular edema and/or serous retinal detachment in the OCT images;
5	(2) persistence or recurrence of dye leakage in the FA images; and (3) new subretinal
6	hemorrhage from the mCNV.
7	The efficacy of IVB for mCNV was based on the BCVA measured at 1, 3, 6, 12, 18, and 24
8	months after the initial IVB. In addition, the change in the BCVA, number of IVBs, and
9	number of serious complications during the 24 months follow-up were evaluated.
10	Paired <i>t</i> tests were used to evaluate the significance of differences in the BCVA at two time
11	points. Pearson's correlation analyses was used to assess the influence of each pre-treatment
12	factor, viz., age in years, duration of symptom in months, axial length in mm, pre-treatment
13	BCVA in logMAR units, pre-treatment CNV size in μ m, and pre-treatment CNV location as
14	subfoveal or juxtafoveal, on the BCVA change, and the BCVA at 24 months after the initial IVB.
15	Stepwise forward multivariate linear regression analyses were also performed to evaluate the
16	contribution of each pre-treatment factor to the BCVA change and the BCVA at 24 months after
17	the initial IBV. These statistical analyses were performed using software R

1	of 1 for subfoveal mCNVs and 0 for juxtafoveal CNVs for the correlation and multiple
2	regression analyses. Stepwise forward regression analyses were performed using the software
3	R package "maSigPro" (<u>http://bioconductor.org/packages/release/bioc/html/maSigPro.html</u>).
4	All continuous values are presented as means \pm standard deviations (SDs). The level of
5	statistical significance was set at $P < 0.05$.
6	
7	Results
8	
9	Twenty-eight eyes of 28 patients met the inclusion criteria. Of these 28 eyes, one eye showed
10	severe inflammation with dense vitreous opacity one day after the fifth IVB and underwent pars
11	plana vitrectomy. ²³ We excluded this eye from the statistical analyses. There were no other
12	severe ocular or systemic adverse effects after the IVB. Of the remaining 27 eyes, four eyes of
13	four patients were lost to follow-up 6 to 18 months after the initial treatment. Then the final
14	number of eyes analyzed was 23 eyes of 23 patients.
15	The demographics of the 23 eyes of 23 patients are shown in Table 1. The mean age of the
16	23 patients (7 men and 16 women) at the time of the initial IVB was 65.1 ± 10.2 years with a
17	range of 39 to 81 years. The mean axial length was 28.94 ± 1.70 mm with a range of 26.50 to

18 32.63 mm. All of the 23 CNVs were predominantly classic on FA, and the CNV was subfoveal

1	in 14 eyes (60.9%) and juxtafoveal in 9 eyes (39.1%). The mean size of the CNV before
2	treatment was $1,803 \pm 725 \ \mu m$ with a range of 750 to $3,750 \ \mu m$. The duration of the symptoms
3	was 3.5 ± 2.2 months with a range of 1.0 to 8.5 months.
4	The mean BCVA before and 1, 3, 6, 12, 18, and 24 months after the initial treatment are
5	shown in Figure 1. The mean pre-IVB BCVA was $0.74 \pm 0.30 \log$ MAR units with a range of
6	0.22 to 1.30 logMAR units. One month after the initial IVB, the mean BCVA improved
7	significantly to 0.43 ± 0.31 logMAR units (<i>P</i> < 0.001; paired <i>t</i> test). The improved BCVA was
8	maintained at 0.46 ± 0.40 logMAR units 24 months after the first treatment ($P < 0.005$). The
9	BCVA in logMAR units was inversely proportional to decimal BCVA, and thus negative values
10	of the mean BCVA change of the 23 eyes was $-0.28 \pm 0.40 \log$ MAR units which indicated that
11	the mean BCVA had improved 24 months after the initial IVB. Of the 23 eyes, 14 eyes
12	(60.9 %) showed a visual improvement of >0.2 logMAR units at 24 months after the first
13	treatment, and two eyes (8.7 %) showed a visual loss of >0.2 logMAR units at 24 months after
14	the first treatment. The mean number of IVB injections performed during the 24 months was
15	1.35 ± 0.71 ; seventeen eyes (73.9 %) had IVB only once; 5 eyes (21.7 %) had IVB twice; and 1
16	eye (4.4 %) required four IVB injections.
17	We next evaluated whether significant correlations existed between pre-treatment factors

18 and the change in the BCVA at 24 months after the initial IVB (Table 2). Pearson's correlation

1	analyses showed that among the pre-treatment factors, the pre-treatment CNV size ($r = 0.45$, P
2	<0.05) and duration of symptoms (r = 0.42, P $<$ 0.05) were positively correlated with the change
3	in the BCVA at 24 months. These results suggested that smaller CNVs and shorter durations of
4	symptoms before the IVB were significantly associated with a greater improvement of the
5	BCVA at 24 months after the initial IVB therapy. The pre-treatment BCVA showed marginally
6	but not significant correlation with the change in the BCVA at 24 months (r = -0.37, $P = 0.087$).
7	The pre-treatment CNV location ($P = 0.27$), age ($P = 0.70$), and axial length ($P = 0.93$) were not
8	significantly correlated with the change in the BCVA.
9	Forward stepwise multiple linear regression analysis with the visual acuity change at 24
10	months as the dependent variable showed that pre-treatment CNV size (standardized β [multiple
11	regression coefficient] = 0.52, $P < 0.01$) and pre-treatment BCVA (standardized β = -0.44, P
12	<0.05) were significant contributing determinants. The duration of symptoms was not included
13	in the stepwise selection procedure. The adjusted R^2 (coefficient of multiple determination) of
14	the final model was 0.333.
15	We also evaluated the possible association of the pre-treatment factors with the BCVA at 24
16	months after the initial IVB treatment (Table 3). Pearson's correlation analyses showed that
17	pre-treatment CNV size and pre-treatment CNV location were significantly associated with
18	BCVA at 24 months (r = 0.56, $P < 0.01$ and r = 0.50, $P < 0.05$, respectively). The duration of the

1	symptoms was also significantly correlated with the BCVA at 24 months (r = 0.49, $P < 0.05$).
2	The pre-treatment BCVA showed marginally but not significant correlation ($r = 0.39$, $P = 0.065$)
3	with BCVA at 24 months after initial treatment. Forward stepwise regression analysis showed
4	that only the pre-treatment CNV size (standardized $\beta = 0.56$, <i>P</i> < 0.01) was included in the final
5	model. The adjusted R^2 of the final model was 0.279.
6	
7	Discussion
8	
9	Although the dose of bevacizumab and follow-up strategy were different among the studies,
10	earlier studies have reported that IVB for mCNV leads to a significant improvement in the
11	BCVA with only a few injections. Thus IVB may be considered as first-line therapy for
12	mCNV. ⁹⁻²² However, the follow-up periods were up to one-year in most of the earlier studies.
13	There have been a few studies that showed two years visual outcomes of IVB for mCNV, and the
14	results have been conflicting. ^{9,18,20} Our results showed that IVB for 23 eyes with mCNV
15	significantly improved the BCVA at one month (from $0.74 \pm 0.30 \log$ MAR units to 0.43 ± 0.31
16	logMAR units), and following an as needed strategy, the BCVA improvement was maintained
17	over 24 months with 1.35 ± 0.71 times IVB. Baba et al. reported that 12 eyes with mCNV
18	treated by 1.25 mg IVB had significant improvement of the BCVA from $0.75 \pm 0.25 \log MAR$

1	units at baseline to 0.50 ± 0.38 logMAR unit at 24 months after IVB, and mean number of
2	injections was 1.6 ± 0.8 times. ⁹ Ikuno et al. reported that 11 eyes with mCNV treated by 1.0
3	mg IVB showed significant improvement of the BCVA from $0.68 \pm 0.29 \log$ MAR units to 0.56
4	\pm 0.31 logMAR unit at one months, and the improvement was maintained for 12 months.
5	However, the significance of the improvement was not present at 18 and 24 months after the
6	initial treatment, and the mean number of injections was 2.9 ± 2.4 times. ¹⁸ Voykov et al
7	reported that 11 eyes treated by 1.25 mg IVB monotherapy showed gradually improvements of
8	the BCVA from 0.7 logMAR units to 0.5 logMAR unit with 2.2 times injections 24 months after
9	IVB, however, the improvement was marginally not significant. ²⁰
10	There are several reasons for the differences of the results of these studies; for example, all
10 11	There are several reasons for the differences of the results of these studies; for example, all four studies were retrospective, the sample sizes were relatively small, and there were
11	four studies were retrospective, the sample sizes were relatively small, and there were
11 12	four studies were retrospective, the sample sizes were relatively small, and there were differences of the baseline characteristics of the patients. Accumulation of the results of more
11 12 13	four studies were retrospective, the sample sizes were relatively small, and there were differences of the baseline characteristics of the patients. Accumulation of the results of more studies as well as prospective studies with a larger number of cohorts will be necessary to
11 12 13 14	four studies were retrospective, the sample sizes were relatively small, and there were differences of the baseline characteristics of the patients. Accumulation of the results of more studies as well as prospective studies with a larger number of cohorts will be necessary to understand the long-term visual prognosis of IVB for mCNV. Several earlier studies also
11 12 13 14 15	four studies were retrospective, the sample sizes were relatively small, and there were differences of the baseline characteristics of the patients. Accumulation of the results of more studies as well as prospective studies with a larger number of cohorts will be necessary to understand the long-term visual prognosis of IVB for mCNV. Several earlier studies also showed that IVB was more effective than photodynamic therapy for treating mCNV. ^{9,12, 18, 19, 21}

1	associated with both the BCVA and the change in the BCVA at 24 months after the initial IVB.
2	These results indicated that eyes with smaller mCNV had both better BCVA itself and better
3	improvement of BCVA at 24 months after the initial IVB than those with larger mCNV. Our
4	results showed that the mCNV size could be used as a prognostic factor for the BCVA after IVB
5	for mCNV. Similar findings were reported for age-related macular degeneration (AMD) where
6	the size of the CNV before PDT or anti-VEGF therapy was a predictive factor for the
7	post-treatment BCVA. ^{8, 24-28} However, the mechanism of how the CNV lesion size influences
8	the visual outcome after these treatments has not been determined.
9	The pre-treatment BCVA was also significantly associated with the change in the post-IVB
10	BCVA at 24 months, but it was not significantly associated with the BCVA itself at 24 months.
11	Thus, patients with poorer BCVA acuity before treatment had greater recovery of the BCVA
12	than those with better pre-treatment BVCA. Similar results were reported in subgroup analyses
13	in the MARINA ²⁵ and ANCHOR studies, ²⁶ both of which were prospective, randomized,
14	double-masked studies that evaluated effectiveness of another anti-VEGF drug, ranibizumab, for
15	the treatment of AMD. In both subgroup analyses, better baseline BCVA, increasing age, and
16	larger CNV lesion size were associated with less improvement of the BCVA after the
17	ranibizumab treatment. The authors suggested that the association between the baseline BCVA
18	and the visual improvement after treatment was because patients with higher pre-treatment

1	BCVAs had a smaller chance for improvement (ceiling effect), whereas patients with a greater
2	impairment of the pre-treatment BCVA had a greater chance for improvement (floor effect). ^{25, 26}
3	We suggest that our results might also be due to the similar ceiling/floor effect, and we should
4	not consider that IVB was less effective for the mCNV patients with better pre-treatment BCVA.
5	An earlier natural history study showed that eyes with juxtafoveal mCNV had better final
6	BCVA than those with subfoveal mCNV. ⁵ The correlation analysis in our study showed that
7	the pre-treatment location (subfoveal or juxtafoveal) of the mCNV was significantly correlated
8	with BCVA at 24 months. However, the forward stepwise regression analysis did not show that
9	the CNV location was a significant contributing determinant for the BCVA at 24 months. This
10	might be partially due to the pre-treatment CNV location was correlated with the pre-treatment
11	CNV size (r = 0.45, $P < 0.05$), i.e., subfoveal mCNVs were larger than juxtafoveal mCNVs in
12	this study. The duration of the symptoms was also correlated with pre-treatment CNV size (r =
13	0.42, $P < 0.05$). This might explain why the forward stepwise regression analysis did not
14	include this covariant into the final models.
15	Although the patients' age has been shown to have influence on natural history and visual
16	outcome after treatment of mCNVs, ^{24, 29-32} it was not significantly associated with visual
17	outcome after IVB treatment in our eyes. The reason might be that most of the patients in this
18	study were older with a mean age of 65.1 ± 10.2 years, and 20 of the 23 patients (87.0%) were

1	over 60-years-of-age. We could not assess the effectiveness of IVB for young patients with
2	mCNV and additional study are needed to determine this.
3	The limitations of this study are its retrospective design and small sample size. The
4	adjusted R^2 of the final regression models was 0.333 and 0.279, indicating that the revealed
5	predictors leave a notable amount of variation of the dependent variables, i.e., the BCVA and the
6	change in the BCVA at 24 months. However, the results of this study showed that IVB
7	followed by as needed strategy led to a rapid and significant visual recovery in patients with
8	mCNV, and the visual recovery was maintained for 24 months after initial treatment. The
9	pre-treatment CNV size was an important prognostic factor that was significantly associated with
10	both the change in the BCVA and the BCVA at 24 months after initial treatment. The results
11	indicated that patients with smaller pre-treatment mCNVs would have better visual recovery and
12	better BCVA at 24 months after initial IVB. The patients with more impaired pre-treatment
13	BCVA had better visual recovery than those with better pre-treatment BVCA, however, these
14	results may be due to ceiling/floor effects.
15	

15

16 Acknowledgements

The authors thank Dr. Christopher Seunkyu Lee, Yonsei University College of Medicine, Seoul,
Korea, for his support in data analysis and interpretation. The study was supported in part by

1	gra	nts-in-aid for scientific research (No. 21249084) from the Japan Society for the Promotion of
2	Sci	ence, Tokyo, Japan, and by the Japanese National Society for the Prevention of Blindness.
3	The	e authors indicate no financial conflict of interest.
4		
5	Re	ferences
6	1.	Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye.
7		Am J Ophthalmol 1971;71:42-53.
8	2.	Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina
9		1992;12:127-133.
10	3.	Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose
11		to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol
12		2003;87:570-573.
13	4.	Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J
14		Ophthalmol 1981;91:177-183.
15	5.	Bottoni F, Tilanus M. The natural history of juxtafoveal and subfoveal choroidal
16		neovascularization in high myopia. Int Ophthalmol 2001;24:249-255.
17	6.	Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a
18		10-year follow-up. Ophthalmology 2003;110:1297-1305.

1	7.	Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in
2		pathologic myopia. Cochrane Database Syst Rev 2005:CD004765.
3	8.	Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal
4		choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical
5		trialVIP report no. 3. Ophthalmology 2003;110:667-673.
6	9.	Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S. Two-year
7		Comparison of Photodynamic Therapy and Intravitreal Bevacizumab for Treatment of
8		Myopic Choroidal Neovascularization. Br J Ophthalmol 2009. forthcoming.
9	10.	Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic
10		choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol
11		2009;93:150-154.
12	11.	Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for
13		choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol
14		2009;147:84-93 e1.
15	12.	Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and
16		regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or
17		after photodynamic therapy. Am J Ophthalmol 2009;148:396-408.
18	13.	Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal

1		neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol
2		2009;147:94-100 e1.
3	14.	Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat
4		subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J
5		Ophthalmol 2009;93:448-451.
6	15.	Scupola A, Tiberti AC, Sasso P, et al. Macular functional changes evaluated with MP-1
7		microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal
8		neovascularization: one year results. Retina 2010;30:739-747.
9	16.	Spielberg L, Leys A. Intravitreal bevacizumab for myopic choroidal neovascularization:
10		short-term and 1-year results. Bull Soc Belge Ophtalmol 2009;(312):17-27.
11	17.	Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal
12		neovascularization: 1-year follow-up. Eye (Lond) 2009;23:2042-2045.
13	18.	Ikuno Y, Nagai Y, Matsuda S, et al. Two-year visual results for older Asian women treated
14		with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J
15		Ophthalmol 2010;149:140-146.
16	19.	Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F. Laser Photocoagulation,
17		Photodynamic Therapy, and Intravitreal Bevacizumab for the Treatment of Juxtafoveal
18		Choroidal Neovascularization Secondary to Pathologic Myopia. Arch Ophthalmol

2010;128:437-442.

2	20.	Voykov B, Gelisken F, Inhoffen W, Voelker M, Ulrich Bartz-Schmidt K, Ziemssen F.
3		Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a
4		decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol
5		2010;248:543-550.
6	21.	Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with
7		verteporfin for treatment of myopic choroidal neovascularization. Retina 2010;30:418-424.
8	22.	Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization
9		in pathologic myopia. Retina 2009;29:1062-1066.
10	23.	Yamashiro K, Tsujikawa A, Miyamoto K, et al. Sterile endophthalmitis after intravitreal
11		injection of bevacizumab obtained from a single batch. Retina 2010;30:485-490.
12	24.	Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic
13		therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol
14		2004;138:434-438.
15	25.	Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup
16		analysis of the MARINA study of ranibizumab in neovascular age-related macular
17		degeneration. Ophthalmology 2007;114:246-252.

18 26. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular

1		age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J
2		Ophthalmol 2007;144:850-857.
3	27.	Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin)
4		therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-1322.
5	28.	Kang S, Roh YJ. One-year results of intravitreal ranibizumab for neovascular age-related
6		macular degeneration and clinical responses of various subgroups. Jpn J Ophthalmol
7		2009;53:389-395.
8	29.	Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal
9		neovascularization in high myopia: a comparison between age groups. Ophthalmology
10		2002;109:712-719.
11	30.	Axer-Siegel R, Ehrlich R, Weinberger D, et al. Photodynamic therapy of subfoveal
12		choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation
13		to age at treatment. Am J Ophthalmol 2004;138:602-607.
14	31.	Hayashi K, Ohno-Matsui K, Yoshida T, et al. Characteristics of patients with a favorable
15		natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol
16		2005;243:13-19.
17	32.	Kojima A, Ohno-Matsui K, Teramukai S, et al. Estimation of visual outcome without
18		treatment in patients with subfoveal choroidal neovascularization in pathologic myopia.


- 1 Graefes Arch Clin Exp Ophthalmol 2006;244:1474-1479.
- $\mathbf{2}$
- 3

1 Figure legends

 $\mathbf{2}$

3	Figure 1. Changes of mean best-corrected visual acuity over 24 months after initial intravitreal
4	bevacizumab therapy for a myopic choroidal neovascularization (mCNV). The squares
5	represent the results of subfoveal mCNVs (n=14), the triangles represent the juxtafoveal mCNVs
6	(n=9), and the circles represent all of the eyes, i.e., sum of the subfoveal and juxtafoveal mCNVs
7	(n=23). Visual acuity was converted to a logarithm of the minimal angle of resolution
8	(logMAR) units. The error-bar represents the standard error of the means (SEMs).

9



Category	Subcategory	Value	
Number of patients (eye)		23 (23)	
Age (year)	$mean \pm SD$	65.1 ± 10.2	
	median (range)	65 (39 to 81)	
Gender, no (%)	Men	7 (30.4%)	
	women	16 (69.6%)	
Axial length (mm)	$mean \pm SD$	28.94 ± 1.70	
	median (range)	28.90 (26.50 to 32.63)	
Refraction of phakic eyes (diopter) ^a	$mean \pm SD$	-12.62 ± 3.47	
	median (range)	-13.06 (-6.85 to -19.50)	
Duration of symptoms (month)	$mean \pm SD$	3.5 ± 2.2	
	median (range)	2.5 (1.0 to 8.5)	
CNV size before treatment (µm)	$mean \pm SD$	$1,803 \pm 725$	
	median (range)	1,700 (750 to 3,750)	
CNV location, no (%)	subfoveal	14 (60.9%)	
	juxtafoveal	9 (39.1%)	

^a For the calculation, 7 eyes (30.4%) that had undergone cataract surgery were

excluded. None of the eyes had undergone corneal refractive surgery.

CNV = choroidal neovascularization, SD = standard deviation.

Covariate	Pearson's correlation analysis		Stepwise forward regression analysis ^a	
(Pre-treatment factors)	r	<i>P</i> -value	Standardized B	<i>P</i> -value
CNV size	0.45	0.032	0.52	0.0082
BCVA (logMAR)	-0.37	0.087	-0.44	0.020
Duration of symptoms	0.42	0.044	not included	-
CNV location	0.24	0.27	not included	-
Age	-0.08	0.70	not included	-
Axial length	0.02	0.93	not included	-

Table 2. Correlation Analysis and Stepwise Forward Regression Analysis to Access the Influence of EachPre-treatment Factor on LogMAR Change at 24 Months after Initial IVB for mCNV.

^a Adjusted R^2 (the coefficient of multiple determination) = 0.333.

BCVA = best-corrected visual acuity; logMAR = logarithm of the minimal angle of resolution; mCNV =

myopic choroidal neovascularization; r = Pearson's correlation coefficient; $\beta =$ regression coefficient.

Covariate	Pearson's correlation analysis		Stepwise forward regression analysis ^a	
(Pre-treatment factors)	r	<i>P</i> -value	Standardized β	<i>P</i> -value
CNV size	0.56	0.0056	0.56	0.0056
CNV location	0.50	0.014	not included	-
Duration of symptoms	0.49	0.019	not included	-
BCVA in logMAR	0.39	0.065	not included	-
Age	0.25	0.24	not included	-
Axial length	-0.22	0.32	not included	-

Table 3. Correlation Analysis and Stepwise Forward Regression Analysis to Access the Influence of EachPre-treatment Factor on BCVA in LogMAR at 24 Months after Initial IVB for mCNV.

^a Adjusted R^2 (the coefficient of multiple determination) = 0.279.

BCVA = best-corrected visual acuity; logMAR = logarithm of the minimal angle of resolution; mCNV =

myopic choroidal neovascularization; r = Pearson's correlation coefficient; $\beta = regression$ coefficient.